Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
Unknown status
Development Center for Biotechnology, Taiwan
Phase 2
2005-09-01
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of
DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of
the sample size we could expect but a positive trend of the efficacy unless the effect size
of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical
investigation such as a phase III study should be carried out in an even larger scale. We
also should be able to obtain valuable experience on the adverse effect of prolonged
(24-week) use of Fo-ti.
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
Unknown status
Program Office, National Science & Technology, Biotechnology & Pharmaceuticals
Phase 2
2005-09-01
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of
DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of
the sample size we could expect but a positive trend of the efficacy unless the effect size
of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical
investigation such as a phase III study should be carried out in an even larger scale. We
also should be able to obtain valuable experience on the adverse effect of prolonged
(24-week) use of Fo-ti.
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
Unknown status
Taipei Veterans General Hospital, Taiwan
Phase 2
2005-09-01
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of
DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of
the sample size we could expect but a positive trend of the efficacy unless the effect size
of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical
investigation such as a phase III study should be carried out in an even larger scale. We
also should be able to obtain valuable experience on the adverse effect of prolonged
(24-week) use of Fo-ti.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
